CDKN3 and cancer: Clearly, CDKN3 seems to be a target in CC, but further study is needed to identify or develop either a small molecule drug that inhibits CDKN3 function specifically in neoplastic cells or an effective systemic delivery strategy to introduce CDKN3-specific siRNAs into cancer cells [62].